DaVita (DVA) competitors & alternatives
Health Care · NYSE
DaVita (DVA)'s top competitors and alternatives — its most similar public companies — include Baxter International (BAX), MANNKIND CORP (MNKD), AKEBIA THERAPEUTICS INC (AKBA), UNICYCIVE THERAPEUTICS INC (UNCY), ARDELYX INC (ARDX), PROKIDNEY CORP CLASS A (PROK), VIEMED HEALTHCARE INC (VMD), CLOVER HEALTH INVESTMENTS CORP CLA (CLOV), MERIT MEDICAL SYSTEMS INC (MMSI), BRIGHTSPRING HEALTH SERVICES INC (BTSG), OPTION CARE HEALTH INC (OPCH) and ASTRANA HEALTH INC (ASTH). These are DaVita's closest public-company peers by sub-industry, sector and business themes and is informational only — not financial advice.
Top DVA competitors & alternatives
-
Baxter InternationalBAXHealth Care
A diversified healthcare company producing sterile IV solutions, infusion systems, parenteral nutrition, inhaled anesthetics, surgical sealants, smart beds,…
$21.74 (as of 2026-07-22) · market cap $11.5B
-
MANNKIND CORPMNKDHealth Care
MannKind is a biopharmaceutical company specializing in drug-device combinations, including inhaled therapies and on-body infusors, to treat cardiometabolic…
$3.84 (as of 2026-07-22) · market cap $1.2B
-
AKEBIA THERAPEUTICS INCAKBAHealth Care
A biopharmaceutical company specialized in kidney disease therapeutics with a commercial portfolio for anemia and mineral metabolism and a pipeline of rare…
$1.26 (as of 2026-07-22) · market cap $349M
-
UNICYCIVE THERAPEUTICS INCUNCYHealth Care
A clinical-stage biotechnology firm developing nanoparticle-based and novel therapies to address significant unmet medical needs in kidney disease.
$5.57 (as of 2026-07-22) · market cap $149M
-
ARDELYX INCARDXHealth Care
Ardelyx commercializes tenapanor-based therapies (IBSRELA for IBS-C, XPHOZAH for kidney disease hyperphosphatemia) with a pipeline of next-generation NHE3…
$5.08 (as of 2026-07-22) · market cap $1.3B
-
PROKIDNEY CORP CLASS APROKHealth Care
ProKidney is pioneering a first-in-class autologous kidney cell therapy to slow kidney function decline in advanced CKD and diabetes patients, currently in…
$1.53 (as of 2026-07-22) · market cap $462M
-
VIEMED HEALTHCARE INCVMDHealth Care
Viemed provides home-based respiratory, chronic care, and women's health services with clinical practitioners delivering therapy and equipment rental to…
$11.92 (as of 2026-07-22) · market cap $456M
-
CLOVER HEALTH INVESTMENTS CORP CLACLOVHealth Care
Clover Health combines Medicare Advantage insurance with a proprietary, AI-driven clinical decision-support platform designed to improve health outcomes and…
$4.67 (as of 2026-07-22) · market cap $2.5B
-
MERIT MEDICAL SYSTEMS INCMMSIHealth Care
Merit Medical Systems is a diversified medical technology company specializing in high-quality, proprietary devices for interventional and diagnostic…
$73.11 (as of 2026-07-22) · market cap $4.4B
-
BRIGHTSPRING HEALTH SERVICES INCBTSGHealth Care
An integrated, national home-based care provider delivering complementary pharmacy and clinical services to medically complex patients to reduce…
$69.74 (as of 2026-07-22) · market cap $13.7B
-
OPTION CARE HEALTH INCOPCHHealth Care
Option Care Health is the nation’s largest independent provider of home and alternate site infusion services, delivering cost-effective, patient-centered care…
$21.15 (as of 2026-07-22) · market cap $3.3B
-
ASTRANA HEALTH INCASTHHealth Care
Astrana Health operates a technology-driven platform that empowers independent physicians and medical groups to transition to and succeed in value-based care…
$41.94 (as of 2026-07-22) · market cap $2.1B
Not quite? Describe exactly what you want →
Peers are DaVita's closest public companies by shared sub-industry, sector and business themes. See the full profile: DaVita (DVA).
Last updated 2026-07-22.
Informational only — NOT financial advice. Company data is sourced from SEC EDGAR + Finnhub and shown with its as-of date.